Literature DB >> 16738904

Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane.

Tomoko Matsumoto1, Toshiyuki Tsurumoto, Hiroyuki Shindo.   

Abstract

To compare the histological appearance of synovial membrane and interleukin (IL)-6 levels in synovial fluids of patients with rheumatoid arthritis (RA). Synovial tissue and synovial fluids were obtained from 51 knee joints with RA undergoing synovectomy or joint replacements. A histological inflammation score was determined based on the hyperplasia of the synovial lining and infiltration of inflammatory cells. The concentrations of IL-6 in synovial fluids were measured by ELISA. The association between IL-6 levels and histological findings was evaluated. We found a positive correlation between the infiltration of inflammation cells in synovial tissues and the concentration of IL-6 in synovial fluids. The IL-6 level in synovial fluid partially reflects histological synovial inflammation.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16738904     DOI： 10.1007/s00296-006-0143-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  18 in total

1.  Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis.

Authors:  P A Klimiuk; S Sierakowski; R Latosiewicz; J P Cylwik; B Cylwik; J Skowronski; J Chwiecko
Journal:  Clin Exp Rheumatol       Date:  2003 Jan-Feb       Impact factor: 4.473

2.  Interleukin 1 induces different cytokines in human fibroblasts.

Authors:  J Van Damme; M R Schaafsma; R Conings; J P Lenaerts; W Put; A Billiau; W E Fibbe
Journal:  Lymphokine Res       Date:  1989

3.  Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor.

Authors:  K Yano; N Nakagawa; H Yasuda; E Tsuda; K Higashio
Journal:  J Bone Miner Metab       Date:  2001       Impact factor: 2.626

Review 4.  Gp130 and the interleukin-6 family of cytokines.

Authors:  T Taga; T Kishimoto
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

5.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

6.  Cytokine production by synovial T cells in rheumatoid arthritis.

Authors:  G Steiner; M Tohidast-Akrad; G Witzmann; M Vesely; A Studnicka-Benke; A Gal; M Kunaver; P Zenz; J S Smolen
Journal:  Rheumatology (Oxford)       Date:  1999-03       Impact factor: 7.580

7.  Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.

Authors:  A Desgeorges; C Gabay; P Silacci; D Novick; P Roux-Lombard; G Grau; J M Dayer; T Vischer; P A Guerne
Journal:  J Rheumatol       Date:  1997-08       Impact factor: 4.666

8.  Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis.

Authors:  P A Klimiuk; S Sierakowski; R Latosiewicz; J P Cylwik; B Cylwik; J Skowronski; J Chwiecko
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

9.  Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis.

Authors:  P P Tak; P A van der Lubbe; A Cauli; M R Daha; T J Smeets; P M Kluin; A E Meinders; G Yanni; G S Panayi; F C Breedveld
Journal:  Arthritis Rheum       Date:  1995-10

10.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.

Authors:  E M Paleolog; S Young; A C Stark; R V McCloskey; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  1998-07
View more
  10 in total

1.  Cadherin-11 regulates fibroblast inflammation.

Authors:  Sook Kyung Chang; Erika H Noss; Mei Chen; Zhizhan Gu; Kirk Townsend; Rosa Grenha; Luis Leon; Soo Young Lee; David M Lee; Michael B Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

2.  Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid.

Authors:  Jennifer Parker; Francisco Atez; Ronald G Rossetti; Ann Skulas; Rakesh Patel; Robert B Zurier
Journal:  Rheumatol Int       Date:  2007-11-27       Impact factor: 2.631

3.  Krüppel-Like Factor 4 Is a Regulator of Proinflammatory Signaling in Fibroblast-Like Synoviocytes through Increased IL-6 Expression.

Authors:  Xinjing Luo; Jie Chen; Jianwei Ruan; Yongfeng Chen; Xuanrong Mo; Jiangwen Xie; Guoju Lv
Journal:  Mediators Inflamm       Date:  2016-06-16       Impact factor: 4.711

Review 4.  Recent advances in neutralizing the IL-6 pathway in arthritis.

Authors:  Charles J Malemud
Journal:  Open Access Rheumatol       Date:  2009-10-05

5.  Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

Authors:  Gerd R Burmester; Yong Lin; Rahul Patel; Janet van Adelsberg; Erin K Mangan; Neil M H Graham; Hubert van Hoogstraten; Deborah Bauer; Juan Ignacio Vargas; Eun Bong Lee
Journal:  Ann Rheum Dis       Date:  2016-11-17       Impact factor: 19.103

6.  Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.

Authors:  Roy Fleischmann; Janet van Adelsberg; Yong Lin; Geraldo da Rocha Castelar-Pinheiro; Jan Brzezicki; Pawel Hrycaj; Neil M H Graham; Hubert van Hoogstraten; Deborah Bauer; Gerd R Burmester
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

7.  Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

Authors:  Vibeke Strand; Laure Gossec; Clare W J Proudfoot; Chieh-I Chen; Matthew Reaney; Sophie Guillonneau; Toshio Kimura; Janet van Adelsberg; Yong Lin; Erin K Mangan; Hubert van Hoogstraten; Gerd R Burmester
Journal:  Arthritis Res Ther       Date:  2018-06-19       Impact factor: 5.156

8.  Proinflammatory soluble interleukin-15 receptor alpha is increased in rheumatoid arthritis.

Authors:  Ana Cecilia Machado Diaz; Araceli Chico Capote; Celia Aurora Arrieta Aguero; Yunier Rodríguez Alvarez; Diana García Del Barco Herrera; Miguel Estévez Del Toro; Gerardo E Guillen Nieto; Alicia Santos Savio
Journal:  Arthritis       Date:  2012-07-25

9.  High sensitivity C-reactive protein is associated with lower tibial cartilage volume but not lower patella cartilage volume in healthy women at mid-life.

Authors:  Fahad S Hanna; Robin J Bell; Flavia M Cicuttini; Sonia L Davison; Anita E Wluka; Susan R Davis
Journal:  Arthritis Res Ther       Date:  2008-02-29       Impact factor: 5.156

10.  Molecular characterisation of the synovial fluid microbiome in rheumatoid arthritis patients and healthy control subjects.

Authors:  Dargham Bayan Mohsen Hammad; Veranja Liyanapathirana; Daniel Paul Tonge
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.